Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~To be eligible, a participant is required to be or have:~* Consented to participate in the LTE and has successfully completed the placebo-controlled 24-week Study AV-101-002.~Key Exclusion Criteria:~Subjects meeting any of the following criteria:~* The Investigator believes that it would not be in the best interest of the subject to be included in the LTE e.g., for clinical or social reasons.~* Subjects who were not compliant with study medication in AV-101-002 as assessed by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Crossover AV-101 10 mg (Type: EXPERIMENTAL): Participants who previously received placebo in AV-101-002 received AV-101 (imatinib) 10 milligrams (mg) administered twice daily (BID) via dry powder inhalation.
- Placebo Crossover AV-101 35 mg (Type: EXPERIMENTAL): Participants who previously received placebo in AV-101-002 received AV-101 (imatinib) 35 mg administered BID via dry powder inhalation.
- Placebo Crossover AV-101 70 mg (Type: EXPERIMENTAL): Participants who previously received placebo in AV-101-002 received AV-101 (imatinib) 70 mg administered BID via dry powder inhalation.
- Continuing AV-101 10 mg (Type: EXPERIMENTAL): Participants who previously received AV-101 10 mg in AV-101-002 received AV-101 (imatinib) 10 mg administered BID via dry powder inhalation.
- Continuing AV-101 35 mg (Type: EXPERIMENTAL): Participants who previously received AV-101 35 mg in AV-101-002 received AV-101 (imatinib) 35 mg administered BID via dry powder inhalation.
- Continuing AV-101 70 mg (Type: EXPERIMENTAL): Participants who previously received AV-101 70 mg in AV-101-002 received AV-101 (imatinib) 70 mg administered BID via dry powder inhalation.

Based on this trial design, predict the completion outcome and termination type (if applicable).